CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

Study acronym: CAR-T，MTD
StatusSuspended
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment suspended Sponsor's reason: Because of changes in domestic regulations, we need to complete the local filing process first before continuing the research.
    • Site details revised
  2. Re-verified, no change to tracked fields
  3. Primary endpoint(s) modified Show 5 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Jul 28, 2025 to Mar 1, 2026
    • Eligibility criteria expanded, about 23 words
    • Site details revised
    • Collaborators: details revised at 1 of 5 entries
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
Trial Details
NCT Number NCT07048353
Lead Sponsor Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Collaborators: Tongji Hospital Affiliated to Tongji Medical College of HUST, Shanxi Bethune Hospital, Wuhan Central Hospital, Yichang Central People's Hospital, First Affiliated Hospital of Guangxi Medical University
Conditions
(from sponsor)		 Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
Related terms Lymphoma, Lymphoma, B-Cell
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov